Form 4: Vera Therapeutics Director, Kimball Hall, Acquires 14,000 Stock Options

Director Kimball Hall acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Summary

• On May 14, 2025, Kimball Hall, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
• The exercise price of these options is $21.19.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through that date.
• The options expire on May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally signals confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continuous service and a potential change in control, suggesting a focus on long-term commitment and alignment with shareholder interests.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which is common practice.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Vera Therapeutics, Kimball Hall, stock options, Form 4, director, beneficial ownership, securities